Aprea Therapeutics Inc. (APRE) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Aprea (APRE)

The financial foundation of Aprea Therapeutics (APRE) relies on developing agents to restore tumor suppressor functions in individuals with p53 mutations. Historical price action on the GURU.Markets platform shows that the EV/EBITDA ratio is 0.00. The company aims for global dominance of the oncology market by expanding its line of DDR inhibitors, implementing robotic molecule screening and automated software for clinical data analysis.

APRE Aprea Therapeutics, Inc.: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/12/2026

APRE (aprea.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Aprea Therapeutics, Inc.|APRE - Fair Value Consensus
- market capitalization indicators:
Market Value Aprea Therapeutics|APRE - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Aprea Therapeutics|APRE - Accounting Capitalization|Market Capitalization to Book Value Ratio aprea.com|APRE - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Aprea Therapeutics|APRE - Long-Term Liabilities to Capital|Short-Term Debt to Equity Aprea Therapeutics, Inc.|APRE - Company Debts|Debt to Book Capitalization Ratio Aprea Therapeutics|APRE - Long-Term Debt|Company Short-Term Debts Aprea Therapeutics|Quick Liquidity Indicator aprea.com
- business earnings and investment ratios data:
APRE - Company Net Income|Future Profit Aprea Therapeutics|APRE - Company Value to Net Income|Projected Price to Earnings Aprea Therapeutics, Inc.|APRE - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Aprea Therapeutics|APRE - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Aprea Therapeutics|APRE - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months aprea.com|APRE - Earnings per share increase in current year|Earnings growth forecast for next year Aprea Therapeutics
Summary company analytics:APRE (Aprea)
Original product of Aprea Therapeutics, Inc.

To objectively assess the fundamental quality of Aprea Therapeutics (APRE), an investor must compare the total enterprise value with its operating profit before depreciation and interest. This method measures the real value of the asset by neutralizing the impact of taxes and debt load, making the EV/EBITDA ratio, accounting for financial leverage, a key indicator of undervaluation. The stability of this metric confirms the efficiency of capital-intensive processes, including strict adherence to climate standards during the transportation of targeted oncology drugs.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Monopar Therapeutics Inc. (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (I-Mab Biopharma Co., Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Fennec (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences Inc. CHRS|Corbus Pharmaceuticals Holdings, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BeyondSpring Inc|BCAB: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple lixte.com LIXT|Enterprise Value to EBITDA Ratio CTXR|Company Value to EBITDA Cellectar Biosciences Inc CLRB|Enterprise Value to EBITDA Ratio BLRX (BioLineRx Corp)|CANF (Can-Fite) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion Therapeutics Corp.)|NuCana Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix Inc.)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Therapeutics (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio, Inc.|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Inc (PRTG)